Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NEOG's Cash to Debt is ranked higher than
92% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. NEOG: No Debt )
NEOG' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: No Debt

Equity to Asset 0.89
NEOG's Equity to Asset is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. NEOG: 0.89 )
NEOG' s 10-Year Equity to Asset Range
Min: 0.72   Max: 0.93
Current: 0.89

0.72
0.93
Interest Coverage No Debt
NEOG's Interest Coverage is ranked higher than
85% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. NEOG: No Debt )
NEOG' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 5
Z-Score: 26.24
M-Score: -2.47
WACC vs ROIC
11.23%
13.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.21
NEOG's Operating margin (%) is ranked higher than
95% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. NEOG: 18.21 )
NEOG' s 10-Year Operating margin (%) Range
Min: 4   Max: 20.75
Current: 18.21

4
20.75
Net-margin (%) 11.66
NEOG's Net-margin (%) is ranked higher than
92% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. NEOG: 11.66 )
NEOG' s 10-Year Net-margin (%) Range
Min: -1.6   Max: 13.23
Current: 11.66

-1.6
13.23
ROE (%) 10.03
NEOG's ROE (%) is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. NEOG: 10.03 )
NEOG' s 10-Year ROE (%) Range
Min: 9.7   Max: 13.38
Current: 10.03

9.7
13.38
ROA (%) 8.91
NEOG's ROA (%) is ranked higher than
91% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. NEOG: 8.91 )
NEOG' s 10-Year ROA (%) Range
Min: 8.86   Max: 11.42
Current: 8.91

8.86
11.42
ROC (Joel Greenblatt) (%) 38.33
NEOG's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. NEOG: 38.33 )
NEOG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.68   Max: 52.57
Current: 38.33

8.68
52.57
Revenue Growth (3Y)(%) 11.10
NEOG's Revenue Growth (3Y)(%) is ranked higher than
85% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. NEOG: 11.10 )
NEOG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3   Max: 26.3
Current: 11.1

-3
26.3
EBITDA Growth (3Y)(%) 7.00
NEOG's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. NEOG: 7.00 )
NEOG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 2.6   Max: 40.6
Current: 7

2.6
40.6
EPS Growth (3Y)(%) 5.90
NEOG's EPS Growth (3Y)(%) is ranked higher than
78% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. NEOG: 5.90 )
NEOG' s 10-Year EPS Growth (3Y)(%) Range
Min: 4.3   Max: 28.4
Current: 5.9

4.3
28.4
» NEOG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NEOG Guru Trades in Q2 2014

Paul Tudor Jones 5,412 sh (New)
Ron Baron 445,596 sh (unchged)
Mario Gabelli 16,500 sh (unchged)
Manning & Napier Advisors, Inc 108,415 sh (-0.12%)
Jim Simons 11,013 sh (-39.82%)
» More
Q3 2014

NEOG Guru Trades in Q3 2014

Jim Simons 81,013 sh (+635.61%)
Ron Baron 445,596 sh (unchged)
Mario Gabelli 16,500 sh (unchged)
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 52,700 sh (-51.39%)
» More
Q4 2014

NEOG Guru Trades in Q4 2014

Mario Gabelli 16,500 sh (unchged)
Ron Baron 445,596 sh (unchged)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 48,565 sh (-7.85%)
» More
Q1 2015

NEOG Guru Trades in Q1 2015

Jim Simons 9,100 sh (New)
Mario Gabelli 16,500 sh (unchged)
Manning & Napier Advisors, Inc 42,745 sh (-11.98%)
Ron Baron 152,000 sh (-65.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NEOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 53.80
NEOG's P/E(ttm) is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 53.80 )
NEOG' s 10-Year P/E(ttm) Range
Min: 20.74   Max: 67.65
Current: 53.8

20.74
67.65
Forward P/E 40.65
NEOG's Forward P/E is ranked higher than
74% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 40.65 )
N/A
PE(NRI) 52.30
NEOG's PE(NRI) is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 52.30 )
NEOG' s 10-Year PE(NRI) Range
Min: 20.08   Max: 67.83
Current: 52.3

20.08
67.83
P/B 4.90
NEOG's P/B is ranked higher than
60% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. NEOG: 4.90 )
NEOG' s 10-Year P/B Range
Min: 1.92   Max: 6.61
Current: 4.9

1.92
6.61
P/S 6.30
NEOG's P/S is ranked lower than
53% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. NEOG: 6.30 )
NEOG' s 10-Year P/S Range
Min: 1.96   Max: 8.35
Current: 6.3

1.96
8.35
PFCF 63.60
NEOG's PFCF is ranked higher than
75% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 63.60 )
NEOG' s 10-Year PFCF Range
Min: 19.71   Max: 375.61
Current: 63.6

19.71
375.61
POCF 43.60
NEOG's POCF is ranked higher than
80% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 43.60 )
NEOG' s 10-Year POCF Range
Min: 14.78   Max: 73.21
Current: 43.6

14.78
73.21
EV-to-EBIT 31.22
NEOG's EV-to-EBIT is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 31.22 )
NEOG' s 10-Year EV-to-EBIT Range
Min: 13.4   Max: 43.4
Current: 31.22

13.4
43.4
PEG 3.85
NEOG's PEG is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 3.85 )
NEOG' s 10-Year PEG Range
Min: 0.93   Max: 5.84
Current: 3.85

0.93
5.84
Shiller P/E 65.40
NEOG's Shiller P/E is ranked higher than
79% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 65.40 )
NEOG' s 10-Year Shiller P/E Range
Min: 23.85   Max: 84.78
Current: 65.4

23.85
84.78
Current Ratio 8.19
NEOG's Current Ratio is ranked higher than
93% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. NEOG: 8.19 )
NEOG' s 10-Year Current Ratio Range
Min: 3.16   Max: 14.54
Current: 8.19

3.16
14.54
Quick Ratio 6.11
NEOG's Quick Ratio is ranked higher than
90% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. NEOG: 6.11 )
NEOG' s 10-Year Quick Ratio Range
Min: 1.55   Max: 10.77
Current: 6.11

1.55
10.77
Days Inventory 141.40
NEOG's Days Inventory is ranked higher than
68% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. NEOG: 141.40 )
NEOG' s 10-Year Days Inventory Range
Min: 130.86   Max: 228.13
Current: 141.4

130.86
228.13
Days Sales Outstanding 71.04
NEOG's Days Sales Outstanding is ranked higher than
74% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. NEOG: 71.04 )
NEOG' s 10-Year Days Sales Outstanding Range
Min: 46.72   Max: 76.57
Current: 71.04

46.72
76.57

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.10
NEOG's Price/Net Cash is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 28.10 )
NEOG' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 194.8
Current: 28.1

3.9
194.8
Price/Net Current Asset Value 13.30
NEOG's Price/Net Current Asset Value is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 13.30 )
NEOG' s 10-Year Price/Net Current Asset Value Range
Min: 1.95   Max: 17.25
Current: 13.3

1.95
17.25
Price/Tangible Book 7.20
NEOG's Price/Tangible Book is ranked higher than
68% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.20 vs. NEOG: 7.20 )
NEOG' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 9.8
Current: 7.2

1.6
9.8
Price/DCF (Projected) 3.10
NEOG's Price/DCF (Projected) is ranked higher than
80% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 3.10 )
NEOG' s 10-Year Price/DCF (Projected) Range
Min: 0.99   Max: 4.25
Current: 3.1

0.99
4.25
Price/Median PS Value 1.50
NEOG's Price/Median PS Value is ranked higher than
60% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. NEOG: 1.50 )
NEOG' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 2.05
Current: 1.5

0.33
2.05
Price/Peter Lynch Fair Value 5.20
NEOG's Price/Peter Lynch Fair Value is ranked higher than
88% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 5.20 )
NEOG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44   Max: 5.84
Current: 5.2

0.44
5.84
Price/Graham Number 4.10
NEOG's Price/Graham Number is ranked higher than
84% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NEOG: 4.10 )
NEOG' s 10-Year Price/Graham Number Range
Min: 0.91   Max: 5.43
Current: 4.1

0.91
5.43
Earnings Yield (Greenblatt) 3.20
NEOG's Earnings Yield (Greenblatt) is ranked higher than
76% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. NEOG: 3.20 )
NEOG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 7.5
Current: 3.2

2.3
7.5
Forward Rate of Return (Yacktman) 11.40
NEOG's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. NEOG: 11.40 )
NEOG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.2   Max: 24.6
Current: 11.4

6.2
24.6

Analyst Estimate

May15 May16
Revenue(Mil) 279 316
EPS($) 0.91 1.13
EPS without NRI($) 0.91 1.13

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NG2.Germany,
Neogen Corporation was formed as a Michigan corporation in June 1981 and actual operations began in 1982. The Company and subsidiaries develop, manufacture, and market a diverse line of products dedicated to food and animal safety. The Company's food safety segment consists of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. These products are marketed by company sales personnel in North America, the United Kingdom and other parts of Europe, Mexico and Brazil and by distributors through the rest of the world. The majority of the tests are disposable, single-use, immunoassay and DNA detection products that rely on the Company's proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. The Company's expanding line of food safety products also includes bioluminescence-based diagnostic technology. It operates in two primary business areas: the Food Safety segment, which develops and markets products for the detection of pathogens, natural toxins, allergens and other unwanted substances in food and feed products; and the Animal Safety segment, which develops and markets products and services dedicated to animal health. The products of food safety segment consist of diagnostic test kits and complementary products marketed to food and feed producers and processors to detect dangerous and/or unintended substances in food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. Animal Safety's NeogenVet product line provides value-added products to the veterinary market. Top NeogenVet products include PanaKare, a digestive aid that serves as a replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency; Natural Vitamin E-AD, which aids in the prevention and treatment of vitamin deficiencies in swine, cattle and sheep; and RenaKare, a supplement for potassium deficiency in cats and dogs. It manufactures its products in Lansing, Michigan; Lexington, Kentucky; Randolph, Wisconsin; and Ayr, Scotland. The Company competes on the basis of ease of use, speed, accuracy, and other similar performance characteristics of its products. It is subject to substantial governmental regulation.
» More Articles for NEOG

Headlines

Articles On GuruFocus.com
comment on NEOG Apr 13 2013 
comment on NEOG Mar 06 2013 
Buffett-Munger Model Portfolio Outperforms Again - June Model Portfolio Performance Update Jun 05 2012 
Focusing on Predictable Companies, Value Strategies Continue to Outperform. Apr 02 2012 
The Most Overpaid and Underpaid CEOs Jan 19 2012 
Value Idea Contest Results Announcement Apr 12 2012 
Neogen: Food and Animal Safety Supplier Serves Long-Term Investors Well Oct 03 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 15,000 Shares Mar 04 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 5,000 Shares Mar 01 2011 
Neogen Corp. (NEOG) Chairman & CEO James L Herbert sells 11,641 Shares Feb 17 2011 

More From Other Websites
Neogen launches lower cost Igenity dairy genomic tests May 19 2015
5 Stocks Insiders Love Right Now Apr 29 2015
Big Earnings Week Keeps Insider Buying Slow but Steady Apr 25 2015
10-Q for Neogen Corp. Apr 24 2015
Neogen disinfectants proven effective against avian influenza Apr 20 2015
NEOGEN CORP Financials Apr 07 2015
Neogen Adds Reveal for Multi-Treenut to Food Allergen Tests - Analyst Blog Apr 01 2015
Neogen launches Reveal® for Multi-Treenut food allergen test Apr 01 2015
NEOGEN CORP Files SEC form 10-Q, Quarterly Report Apr 01 2015
Neogen launches Reveal® for Multi-Treenut food allergen test Mar 31 2015
NEOGEN CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 30 2015
Neogen CEO adopts 10b5-1 Trading Plan Mar 27 2015
Neogen Lags Q3 Earnings & Revenue Estimates, Stock Down - Analyst Blog Mar 27 2015
NEOGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 27 2015
Neogen CEO adopts 10b5-1 Trading Plan Mar 27 2015
Neogen reports 13% increase in net income Mar 26 2015
Neogen misses Street 3Q forecasts Mar 26 2015
Neogen misses Street 3Q forecasts Mar 26 2015
Neogen reports 13% increase in net income Mar 26 2015
Medical Stocks Among The Latest Breakouts Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK